Reducing Stelara dose in Crohn's and colitis remission
Treatments studied
Part of Digestive system clinical trials.
This trial studies whether people with Crohn's disease or ulcerative colitis who are in deep remission can safely reduce their dose of ustekinumab (Stelara) without the disease coming back. It aims to reduce medication burden while keeping patients well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your Crohn's disease or ulcerative colitis must be in remission (no active symptoms, normal tests, and a healthy look inside your gut).
- You cannot be taking any steroid medications (like prednisone) now or have used them in the last 6 months.
- You must be on only one biologic drug (like Stelara, Remicade, or Humira) — not two or more.
- You must be able to attend follow-up visits and provide consent. If you have issues with alcohol or drug use that might interfere, you cannot join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is comparing two biologic medicines, ustekinumab (Stelara) and infliximab (Remicade), to see which one works better for moderate to severe ulcerative colitis. It is for people who have never taken a biologic before.
This study checks if it's acceptable for people with Crohn's disease to switch from the biologic medicine Stelara to a similar, lower-cost version called Uzpruvo. If you have been stable on Stelara for at least 6 months without needing steroids, you may be able to participate.
This trial tests if checking a stool marker (fecal calprotectin) early after surgery can guide treatment with ustekinumab to prevent Crohn's disease from coming back. It's for people who had certain bowel surgery and have at least one risk factor for recurrence.
This trial tests whether people with ulcerative colitis who have been in deep remission (no signs of active disease) can safely reduce or stop their current medication. It aims to find out if careful monitoring can keep them healthy without full-dose treatment.
This trial tests whether switching from the drug ustekinumab to another drug called guselkumab can help people with active inflammatory bowel disease (IBD) who didn't get enough benefit from ustekinumab. It focuses on people with Crohn's disease or ulcerative colitis who still have signs of inflammation in their gut.
This study looks at how well Ustekinumab (Stelara) works for Crohn's disease in people who started the medication in 2024. Researchers want to understand its real-world benefits and safety.
Hear when a new Crohn Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.